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Summary
Background The COVID-19 pandemic has adversely affected population mental health. We aimed to assess temporal 
trends in primary care-recorded common mental illness, episodes of self-harm, psychotropic medication prescribing, 
and general practitioner (GP) referrals to mental health services during the COVID-19 emergency in the UK.
Methods We did a population-based cohort study using primary care electronic health records from general practices 
registered on the UK Clinical Practice Research Datalink (CPRD). We included patient records from Jan 1, 2010, to 
Sept 10, 2020, to establish long-term trends and patterns of seasonality, but focused primarily on the period 
January, 2019–September, 2020. We extracted data on clinical codes entered into patient records to estimate the incidence 
of depression and anxiety disorders, self-harm, prescriptions for antidepressants and benzodiazepines, and GP referrals 
to mental health services, and assessed event rates of all psychotropic prescriptions and self-harm. We used mean-
dispersion negative binomial regression models to predict expected monthly incidence and overall event rates, which 
were then compared with observed rates to assess the percentage reduction in incidence and event rates after 
March, 2020. We also stratified analyses by sex, age group, and practice-level Index of Multiple Deprivation quintiles.
Findings We identified 14 210 507 patients from 1697 UK general practices registered in the CPRD databases. In 
April, 2020, compared with expected rates, the incidence of primary care-recorded depression had reduced by 43·0% 
(95% CI 38·3–47·4), anxiety disorders by 47·8% (44·3–51·2), and first antidepressant prescribing by 36·4% 
(33·9–38·8) in English general practices. Reductions in first diagnoses of depression and anxiety disorders were 
largest for adults of working age (18–44 and 45–64 years) and for patients registered at practices in more deprived 
areas. The incidence of self-harm was 37·6% (34·8–40·3%) lower than expected in April, 2020, and the reduction was 
greatest for women and individuals aged younger than 45 years. By September, 2020, rates of incident depression, 
anxiety disorder, and self-harm were similar to expected levels. In Northern Ireland, Scotland, and Wales, rates of 
incident depression and anxiety disorder remained around a third lower than expected to September, 2020. In 
April, 2020, the rate of referral to mental health services was less than a quarter of the expected rate for the time of 
year (75·3% reduction [74·0–76·4]).
Interpretation Consequences of the considerable reductions in primary care-recorded mental illness and self-harm 
could include more patients subsequently presenting with greater severity of mental illness and increasing incidence 
of non-fatal self-harm and suicide. Addressing the effects of future lockdowns and longer-term impacts of economic 
instability on mental health should be prioritised.
Funding National Institute for Health Research and Medical Research Council.
Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 
4.0 license.
Introduction
The COVID-19 pandemic has had major implications for 
population mental health,1–4 and it is estimated that up 
to 10 million people in England will require new or 
additional mental health support as a result of the 
pandemic.5 A national lockdown was imple mented in the 
UK on March 23, 2020, with measures eased gradually 
from May, 2020. Although the first local lockdown was 
introduced in late June, 2020, social restrictions 
were reduced in most areas of the UK from June to 
August, 2020. In September, 2020, the number of 
confirmed COVID-19 cases began to increase and new 
restrictions to control transmission of the virus were 
implemented in October, 2020, in England, Northern 
Ireland, Scotland, and Wales. These measures to contain 
the virus have resulted in widespread societal disruption 
and economic downturn.4 Following previous economic 
recessions, the incidence and prevalence of mental 
illness, self-harm, and suicide has increased,6,7 although 
the full economic impact of the COVID-19 pandemic is 
not yet known.
Evidence from self-report surveys indicates that short-
term increases in the prevalence of mental illness, self-
harm, and suicidal ideation might have occurred after 
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implementation of the UK lockdown in March, 2020.8–11 
Such increases are concerning because non-fatal 
self-harm is a strong risk factor for suicide.4,12 Direct 
comparison of prevalence of mental health disorders 
before and after the COVID-19 pandemic is challenging; 
however, available evidence indicates that, to date, the 
prevalence of anxiety and depression during the 
pandemic has been higher than would be expected for 
the general population.9 Public health messages in the 
UK initially encouraged patients to avoid attending 
general practices and hospitals to help control the 
virus. WHO reported substantial disruptions to mental 
health services in 130 countries.13 In Salford, England, 
compared with expected levels, presentations for 
common mental illnesses declined by 50% between 
March and May, 2020.14 Understanding how primary 
care-recorded mental illness and self-harm was affected 
by the various stages of the COVID-19 pandemic will 
indicate the extent of potential unmet need among 
specific patient groups.
Identifying gaps in mental health care has been 
specified as an urgent research priority in the response to 
COVID-19.1 There are specific concerns for certain 
demographic groups, including those at elevated risk of 
severe illness from COVID-19, such as older adults and 
people with underlying predisposing health conditions.1 
Usual clinical care and social support for people with 
pre-existing mental illnesses are likely to have been 
disrupted, which could exacerbate symptoms.1 Young 
adults are also at risk from deterioration in their 
mental health,9,11,15 although some studies have reported 
improved mental health during lockdown among this 
age group.16 Increased unemployment and financial 
insecurity are likely to have more severe ramifications for 
socially disadvantaged groups than less disadvantaged 
groups,2 leading to concerns that the pandemic could 
widen pre-existing inequalities. In the UK, rates of 
COVID-19 infection have been disproportionately higher 
in deprived communities.15,17 To date, most evidence 
regarding the mental health impact of COVID-19 at the 
national level is from self-report surveys.11,18 However, 
individuals with pre-existing mental illnesses and older 
adults are less likely to complete such surveys, which 
could potentially mask the effects of COVID-19 on these 
groups.18
In this study, we used a large primary care longitudinal 
dataset, broadly representative of the UK population, to 
investigate the incidence of primary care-recorded 
common mental illnesses, self-harm, psycho tropic 
medication pre scribing, and general practitioner (GP) 
referrals to mental health services, and event rates of all 
psychotropic medication prescribing and self-harm 
episodes between January, 2019, and September, 2020. 
We also assessed the provision of primary care for 
mental illness across different population subgroups 
during the emergency.
Research in context
Evidence before this study
We searched Web of Science and PubMed from database 
inception to Oct 16, 2020, for articles published in English using 
the search terms “TITLE (covid* OR coronavirus OR 
sars-cov-2) AND TITLE or ABSTRACT (suic* OR self-harm* 
OR self-injur* OR self-poison* OR depress* OR anxi* OR mental* 
OR psych*)”. We also searched the medRxiv server for preprints 
of articles in the primary care research and psychiatry and 
clinical psychology sections. We did additional searches of the 
websites of public sector bodies for relevant reports. 
International evidence from surveys suggests that depression, 
anxiety disorders, and self-harm have become more common 
since the start of the COVID-19 pandemic. However, surveys of 
clinicians and analysis of local electronic health records have 
found substantial reductions in clinical presentations of 
mental illness. To date, no evidence is available on national 
presentation rates for specific mental health disorders among 
demographic subgroups of patients.
Added value of this study
To our knowledge, this is the first population-based study to 
assess the effect of COVID-19 on primary care-recorded mental 
illness and self-harm in the UK. On the basis of data from more 
than 14 million patients registered in general practices across 
the four nations of the UK, we found substantial reductions in 
first diagnoses of depression and anxiety disorders and incident 
self-harm compared with expected rates. Reductions were 
largest for adults of working age, women and younger people 
(aged <45 years) seeking help for self-harm, and patients 
registered at practices in areas with higher levels of deprivation. 
By September, 2020, the incidence of primary care-recorded 
self-harm and mental illness had returned to, or was close to, 
expected rates in England.
Implications of all the available evidence
Despite evidence of increased mental health burden due to the 
COVID-19 pandemic, marked reductions in primary care 
contact for mental illness were observed from April, 2020. 
Consequences of this unmet need could include increases in 
severity of mental illness, increases in self-harm and suicide 
rates, and widening of existing health inequalities. Addressing 
delays in diagnosis and management could help avoid 
increased burden of mental illness, particularly in adults of 
working age, among women and younger people seeking 
help for self-harm, and patients living in deprived areas. 
Health services need to be aware of potential reductions in 
patient contact as the UK enters subsequent lockdowns and 
of possible increases in demand for mental health care in the 
future.
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Methods
Study design, data sources, and participants
For this population-based cohort study, we used 
primary care electronic health records obtained from the 
Clinical Practice Research Datalink (CPRD) Aurum 
and GOLD databases.19,20 We included patient records from 
Jan 1, 2010, to Sept 10, 2020. Pre-pandemic data were 
included to establish long-term trends and patterns of 
seasonality; however, we focused primarily on reporting 
observed versus expected rates between January, 2019, and 
September, 2020. CPRD Aurum includes primary care 
data from contributing general practices in England that 
use the EMIS clinical system, and CPRD GOLD includes 
data from contributing practices in all four UK nations and 
is extracted from the Vision system. The CPRD GOLD 
dataset is broadly representative of the UK population 
with regards to age and sex,19 and CPRD Aurum is 
broadly representative of geographical coverage, area-level 
deprivation, age, and sex in England.20 The CPRD contains 
anonymised consultation records and includes patient 
demographic information, symptoms, diagnoses, medi-
cation prescriptions, and referrals to secondary care. We 
also obtained practice-level data on Index of Multiple 
Deprivation (IMD) quintiles (2014 IMD for Wales; 
2015 IMD for England; 2016 IMD for Scotland; 2017 IMD 
for Northern Ireland).21 The IMD indicates relative 
deprivation at the area level, and is derived from several 
domains and aggregated as a single composite score that is 
ranked within each UK nation.
All individuals aged 10 years and older were eligible for 
inclusion. For each patient, we defined a so-called period 
of eligibility for study inclusion, which commenced on 
the latest of: the study start date (Jan 1, 2010); the patient’s 
most recent registration with their practice; or the date 
on which data from the practice was deemed up-to-
standard by the CPRD.19 A patient’s period of eligibility 
ended on the earliest of: registration termination; the 
end of data collection from their practice; or death. For 
incident cases, we also applied a retrospective analysis 
period during which a patient was required to have been 
registered for at least 1 year before an incident episode.
The study was approved by the Independent Scientific 
Advisory Committee for CPRD research (20_094R1). All 
patient data were de-identified; thus, the requirement for 
patient consent was waived. Individual patients can opt 
out of sharing their records with the CPRD. A summary 
of the study protocol is available online.
Outcomes
The outcomes of the study were incidence of specific 
common mental illness diagnoses (depression and 
anxiety disorders), prescriptions for antidepressants 
and benzodiazepines (the most commonly prescribed 
psychotropic medication types), GP referrals to mental 
health services (such as clinical psychology, psychotherapy, 
and outpatient mental health services), and episodes of 
self-harm. Information on referrals to mental health 
services was available only for practices in Northern 
Ireland, Scotland, and Wales (obtained from the GOLD 
dataset). Further outcomes were event rates of all 
psychotropic prescriptions and self-harm. We did not 
assess event rates for depression or anxiety disorders 
because typically GPs only code longer-term conditions 
once. Therefore, patients might subsequently visit with 
symptoms of depression or anxiety, but without additional 
diagnostic coding.
We used a broad definition of self-harm that captured 
episodes of varying suicidal intent, which aligned with the 
definition used in UK National Institute for Health 
and Care Excellence guidance.22 Considering the relatively 
large number of hospital presentations for self-harm in the 
UK, this outcome is likely to include higher proportions of 
secondary care-treated episodes in our study. We included 
all primary care-recorded codes for depression, anxiety, 
and self-harm, some of which would have been added 
to a patient’s record following a hospital presentation 
or outpatient appointment. Mental illness, self-harm 
episodes, and prescriptions for psychotropic medication 
were identified from Read/SNOMED/EMIS codes used in 
CPRD GOLD and CPRD Aurum databases. All code lists 
were verified by two senior clinical academics (CAC-G, 
NK) and medication lists were reviewed by a senior 
academic pharmacist (DMA).
The first recorded code for each outcome category 
(anxiety, depression, self-harm, antidepressant or benzo-
diazepine prescription, and mental health referral) was 
included as an incident episode. Event rates included all 
specified codes for multiple self-harm or antidepressant 
or benzodiazepine prescriptions recorded in patients’ 
primary care records, regardless of whether the code was 
the individual’s first or subsequent recorded code of 
that type. Individuals could contribute to the incidence 
counts for more than one outcome (eg, mental illness 
diagnosis, psychotropic medication prescription, or self-
harm episode). The denominator for both incidence and 
event rates was the aggregate person-months at risk for the 
whole population or subgroup of interest. The denominator 
for estimating rates of first referral to mental health 
services was person-months among patients diagnosed 
with depression or an anxiety disorder or a recorded 
episode of self-harm on or before referral date. Incidence 
and overall event rates were stratified by sex, age group 
(10–17, 18–44, 45–64, 65–79, and ≥80 years), and practice-
level deprivation (IMD quintiles).
Data analysis
The Aurum and GOLD databases were analysed 
separately, with data from Aurum restricted to English 
practices and GOLD providing information on practices 
in Northern Ireland, Scotland, and Wales. We structured 
data in a time-series format with incident and all event 
counts and person-months at risk aggregated (by year 
and month) with stratification by sex, age group, and 
deprivation quintile.
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We used mean-dispersion negative binomial 
regression models to estimate expected monthly 
incident and all event counts from March, 2020, on the 
basis of predicted rates using data collected in the 
10 years before the pandemic (Jan 1, 2010–Feb 29, 2020). 
The natural logarithm of the denominator (person-
months at risk) was used as an offset in each regression 
model. To account for possible seasonality and long-
term linear trends, we fitted calendar month as a 
categorical variable and time as a continuous variable 
with the number of months since the start of the study 
as the unit of measurement. For each month studied, 
observed and expected incident and all event counts 
were converted to rates using the observed person-
month denominator. We plotted monthly expected rates 
and corresponding 95% CIs against the observed 
rates. Since the rates shared a common denominator, 
differences between expected and observed monthly 
rates were expressed as the relative rate reduction, and 
were calculated by subtracting the observed incident 
and all event counts from the predicted counts and 
dividing by the predicted counts. Relative rate 
reductions in incident and event rates were calculated 
for two time periods: March 1–Sept 10, 2020 (to 
represent the time from when the pandemic began to 
have an effect on primary care-recorded mental illness 
and self-harm to the end of our study period), and 
April 1–May 1, 2020 (to represent the first month after 
the initial reduction in primary care-recorded mental 
illness and self-harm was observed). Relative rate 
reductions are expressed as percentages with 95% CIs. 
The cohort was restricted to patients with records that 
were deemed acceptable by the CPRD for research 
purposes, which excluded patients with missing data 
on sex or age. IMD data were missing for 7·8% of 
the study population in CPRD Aurum and 4·5% of 
the study population in CPRD GOLD (appendix p 15). 
We excluded practices with missing IMD data from 
IMD-stratified analyses; to check for effects of missing 
data, we did a post-hoc analysis of incidence for patients 
from practices with versus those without missing 
IMD data. Data analysis was done using Stata 
(version 16).
This study was done in accordance with REporting 
of studies Conducted using Observational Routinely-
collected health Data guidance (appendix p 20).23
A panel of service users and carers with lived 
experience of mental health services worked with 
the research team to interpret the study’s results. The 
group is linked with the National Institute for 














Incidence (per 100 000 person-months)
Depression 53 443 62 032 13·8% (6·7 to 20·4) 4964 8724 43·0% (38·3 to 47·4)
Anxiety disorders 38 189 51 947 26·4% (21·4 to 31·2) 3807 7305 47·8% (44·3 to 51·2)
Antidepressants 93 845 113 575 17·3% (14·1 to 20·5) 10 512 16 537 36·4% (33·9 to 38·8)
Benzodiazepines 36 762 46 239 20·4% (17·7 to 23·1) 5510 6602 16·5% (13·6 to 19·3)
Self-harm 8512 10 388 18·0% (14·3 to 21·5) 920 1476 37·6% (34·8 to 40·3)
Event rate (per 100 000 person-months)
Antidepressants 7 237 716 7 573 286 4·4% (1·4 to 7·3) 1 031 928 1 120 229 7·8% (4·9 to 10·7)
Benzodiazepines 818 541 853 967 4·1% (1·5 to 6·7) 121 786 126 669 3·8% (1·2 to 6·4)
Self-harm 24 109 29 716 18·8% (15·8 to 21·7) 2666 4206 36·6% (34·2 to 38·8)
Northern Ireland, Scotland, and Wales
Incidence (per 100 000 person-months)
Depression 4601 8714 47·1% (44·1 to 50·1) 451 1305 65·4% (63·4 to 67·3)
Anxiety disorders 3655 6178 40·8% (38·1 to 43·3) 401 944 57·5% (55·5 to 59·3)
Antidepressants 18 081 24 817 27·1% (24·3 to 29·8) 2093 3824 45·2% (43·1 to 47·2)
Benzodiazepines 9342 11 480 18·6% (15·6 to 21·4) 1400 1706 17·9% (14·8 to 20·8)
Self-harm 1808 1988 9·0% (2·8 to 14·8) 230 305 24·5% (19·2 to 29·4)
Referral to mental health 
services
1337 2540 47·3% (44·7 to 49·8) 97 393 75·3% (74·0 to 76·4)
Event rate (per 100 000 person-months)
Antidepressants 1 721 824 1 803 768 4·5% (1·7 to 7·2) 257 671 278 751 7·5% (4·9 to 10·1)
Benzodiazepines 273 154 277 139 1·4% (–1·1 to 3·9) 42 717 42 996 0·6% (–1·9 to 3·2)
Self-harm 4433 4747 6·6% (1·2 to 11·7) 526 716 26·5% (22·3 to 30·6)
Table: Percentage reductions in incidence and event rates of common mental illness, self-harm, antidepressant and benzodiazepine prescribing, 
and referrals to mental health services in the UK between March 1 and Sept 10, 2020
See Online for appendix
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Health Research Greater Manchester Patient Safety 
Translational Research Centre. We used GRIPP2-SF 
reporting checklists to report service user involvement 
(appendix p 16).24
Role of the funding source
The study funders had no role in the study design, data 
collection, data analysis, data interpretation, or writing of 
the report. All authors had full access to the data reported 
in the study and the final responsibility to submit for 
publication.
Results
The study population included 11 946 696 patients from 
1362 general practices in England and 2 263 811 patients 
from 335 general practices in Northern Ireland, 
Scotland, and Wales. 84 general practices in England 
included in the GOLD database were excluded from the 
study to avoid overlap between any practices that 
switched system to prevent duplication of data from 
practices that might be included in both databases. 
24 897 725 patients (21 308 886 from CPRD Aurum; 
3 588 839 from CPRD GOLD) contributed data for the 
Figure 1: Expected and observed incidence of mental illness diagnoses, psychotropic medication prescriptions, and self-harm episodes in England 
(January, 2019–September, 2020)
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estimation of the expected rates in the pre-COVID-19 
comparison period (Jan 1, 2010–Feb 29, 2020). Detailed 
demographic and summary data, including person-time 
(used to model trends in expected rates and to compare 
observed and expected rates) and total numbers of 
diagnoses and events analysed for the study cohorts, are 
included in the appendix (pp 17–18).
In English general practices, in April, 2020, incident 
diagnoses of depression and anxiety disorders, anti-
depressant prescribing, and self-harm all decreased 
substantially compared with expected rates. In England, 
between April 1 and May 1, 2020, the incidence of primary 
care-recorded depression decreased by 43·0% (95% CI 
38·3–47·4), anxiety disorders by 47·8% (CI 44·3–51·2), 
first antidepressant prescribing by 36·4% (33·9–38·8), 
and self-harm by 37·6% (34·8–40·3; table). Subsequently, 
incidence for diagnosis of depression and anxiety dis-
orders, antidepressant prescribing, and self-harm in-
creased in May and June, 2020, and by September, 2020, 
rates were similar to expected rates (figure 1). The 
decrease in incidence of benzodiazepine prescribing was 
less pronounced in April, 2020, and the incidence 
remained lower than expected up to September, 2020.
When considering event rates for all prescribing and 
self-harm episodes in English practices (ie, not just 
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Figure 2: Incidence of mental illness diagnoses, psychotropic medication prescriptions, and self-harm episodes in England, stratified by sex (January, 2019–
September, 2020)
Vertical lines shows March 1, 2020.
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for patients with a history of mental illness or self-harm. 
For example, 10 512 (1%) of 1 031 928 anti depressant 
prescriptions in April, 2020, were first prescriptions. For 
the period April 1 to May 1, 2020, the event rates for 
antidepressant and benzodiazepine prescribing were 
slightly lower than expected (7·8% relative rate reduction 
[95% CI 4·9–10·7 for antidepressants; 3·8% [1·2–6·4] 
for benzodiazepines; table; appendix p 2). Although 
the event rates for self-harm increased in May and 
June, 2020, rates remained lower than expected levels in 
September, 2020 (appendix p 2).
Temporal changes in the incidence of primary care-
recorded depression, anxiety disorders, self-harm and 
prescribing in Northern Ireland, Scotland, and Wales 
differed from those in England. The incidence of 
depression and anxiety disorders increased after 
April, 2020, but rates remained around a third lower 
than expected until September, 2020 (appendix p 6). 
Furthermore, the cumulative difference between observed 
and expected rates of incident primary care-recorded 
depression and anxiety and first antidepressant 
prescribing between April and September, 2020, was 



































































































































































































































































































A Depression B Anxiety disorders
 
Figure 3: Incidence of mental illness diagnoses, psychotropic medication prescriptions, and self-harm episodes in England, stratified by age group 
(January, 2019–September, 2020)
Vertical lines show March 1, 2020.
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larger in practices from Northern Ireland, Scotland, and 
Wales than England (table). Although the incidence of 
self-harm increased to expected rates in June and 
July, 2020, a reduction was observed in August and 
September, 2020 (appendix p 6). In April, 2020, the 
observed rate of referral to mental health services was less 
than a quarter of the expected rate for the time of year 
(75·3% reduction [95% CI 74·0–76·4; table; appendix p 6). 
Referral rates increased between May and August, 2020, 
but remained considerably lower than the expected rates 
for September, 2020.
In England, patterns of incidence and overall event 
rates for depression, anxiety disorders, and psychotropic 
medication prescribing were similar for men and 
women, although rates were consistently higher among 
women than men for all outcomes (figure 2; appendix 
p 3). In April, 2020, observed incidence and event rates 
for self-harm were substantially lower than expected for 
women and people aged younger than 45 years (figure 3). 
Self-harm incidence increased from August, 2020, in the 
10–17-year age group (figure 3). Adults of working age 
(18–44 and 45–64 years) had the largest absolute decreases 
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Figure 4: Incidence of mental illness diagnoses, psychotropic medication prescriptions, and self-harm episodes in England, stratified by Index of Multiple 
Deprivation quintiles (January, 2019–September, 2020)
Vertical lines show March 1, 2020.
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and relative reductions in primary care-recorded 
diagnosis of depression and anxiety disorders in 
April, 2020 (figure 3). A marked increase was observed in 
first benzodiazepine pre scribing for adults aged 80 years 
and older in April 2020, after which rates gradually 
returned to expected levels (figure 3). The incidence of 
depression, anxiety disorders, and self-harm decreased 
for all practice-level IMD quintiles from April, 2020, with 
the largest reductions observed in the most deprived 
populations (figure 4). In a post-hoc analysis, practices 
with missing IMD data had similar rates of mental 
illness, self-harm, and prescribing to practices where 
IMD was known (appendix p 14). By September, 2020, 
the incidence of depression and anxiety disorders in 
all deprivation quintiles had increased. In Northern 
Ireland, Scotland, and Wales, practices in less deprived 
areas had the highest rates of referral to mental health 
services before March, 2020, and the largest subsequent 
reductions from April, 2020 (data not available for 
English practices; appendix p 9).
Discussion
Following the onset of the COVID-19 pandemic, in 
April, 2020, the incidence of primary care-coded 
depression, anxiety disorders, antidepressant prescribing, 
and self-harm decreased sharply compared with expected 
rates in all four UK nations. Rates in England increased 
in May and June, 2020, and by September, 2020, were 
similar to expected rates. In Northern Ireland, Scotland, 
and Wales, a larger reduction in rates persisted until 
September, 2020. Initial decreases in incidence of self-
harm were higher in women and individuals younger 
than 45 years, and adults of working age had the largest 
reductions in primary care-recorded depression and 
anxiety disorders. Decreases in the incidence of 
depression, anxiety disorders, and self-harm were 
observed for all practice-level IMD quintiles from 
April, 2020, with the largest reductions observed in the 
most deprived populations.
In early March, 2020, health services were required to 
balance infection control with access to care for patients, 
and GPs were advised to minimise the number of face-
to-face patient contacts.25 The initial recovery in rates 
of primary care contact after May, 2020, among all 
demographic groups, towards expected rates by 
September, 2020, suggests that GPs adapted rapidly to 
increasing demands for care. We found that the event 
rates for antidepressant and benzodiazepine prescribing 
decreased slightly in the months after the COVID-19 
pandemic began. Electronic repeat prescribing is 
likely to have mitigated against larger decreases in 
prescriptions. This finding could also indicate that some 
patients might have contacted their GP to discuss 
medication needs in preparation for the lockdown. The 
increase in benzodiazepine prescribing in patients aged 
80 years and older in April, 2020, might reflect increased 
anxiety associated with fear of COVID-19 infection, 
changes to care home environments, and the effect of 
shielding in this age group. We observed reductions in 
help seeking for adults of working age, self-harm among 
women and younger people, and those registered with 
practices located in more deprived areas—groups that 
have also been identified as experiencing greater 
deterioration in mental health due to the pandemic.9,10,15,26
The COVID-19 pandemic has affected deprived 
communities in the UK disproportionately: COVID-19 
mortality rates in the most deprived areas are twice as 
high as mortality rates in the least deprived areas.27 The 
restrictions on non-urgent care and the decreases 
in emergency department attendance are also likely 
to have affected socioeconomically disadvantaged 
groups to a greater extent.26 Our findings suggest that 
people from deprived communities were affected 
disproportionately: patients registered with practices in 
deprived areas were observed to have the largest 
decreases in primary care-recorded mental illness and 
self-harm and referrals to mental health services. By 
contrast, before March, 2020, people registered with 
practices located in more deprived areas had the 
highest incidence of depression, anxiety disorders, and 
self-harm. Using survey data, one study found that 
socioeconomic deprivation was associated with higher 
risks of depression and anxiety disorders in adults and 
young people during the COVID-19 pandemic compared 
with pre-pandemic levels.11 The inverse care law, which 
describes the combination of greater health care need 
among people living in deprived areas and the lack of 
additional availability of health services in these areas to 
meet increased demand,28 has previously been 
demonstrated in relation to primary care management 
of self-harm, with lower referral rates associated with 
higher incidence and higher levels of deprivation.29 Our 
findings suggest that COVID-19 has widened such 
inequalities, and have implications for general practices 
in deprived areas managing potential demand.
Our findings regarding event rates suggest a temporary 
but marked reduction in the number of people with 
existing mental illness accessing primary care following 
an episode of self-harm. Primary care is a vital resource 
and support for people with mental illness. One study of 
people who died by suicide found that primary care 
was the most commonly used point of contact in the 
week before suicide.12 Ensuring that access to treatment is 
available for people with mental illness, who might 
require regular contact and support, and for whom 
physical distancing restrictions might exacerbate 
symptoms, is crucial.1 Evidence from the South London 
and Maudsley National Health Service (NHS) Trust in 
London, UK, showed that caseloads for community 
mental health teams remained relatively stable between 
March and May, 2020, whereas a marked reduction in 
caseload was observed for home treatment teams.30 
Consistent with our findings, this suggests that some 
people experiencing a mental health crisis, who would 
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have been expected to receive treatment, did not access 
primary care during the COVID-19 restrictions.
Monitoring patterns in primary care recording of 
mental illness diagnoses and self-harm episodes after 
September, 2020, will provide crucial information on 
equity of care for specific health conditions and between 
patient groups. Obtaining such data will also help to 
assess how ongoing restrictions intended to limit the 
spread of COVID-19, alongside the potential impact 
on population mental health, continue to affect help 
seeking. This evidence will enable public mental health 
interventions to be targeted to groups most in need, a key 
mechanism for reducing the mental health impact of 
COVID-19.1 Although event rates in this study mostly 
represented people with existing mental illness, future 
work should focus specifically on this group, and on 
people with a history of self-harm. Survivors of COVID-19 
are more susceptible to mental illness, fatigue, and 
so-called long COVID,31 and patients who received critical 
care are at particular risk of post-traumatic stress 
disorder.32 Future work should investigate these longer-
term outcomes among COVID-19 survivors. Further 
research is also needed on the mental health effects of 
COVID-19 containment restrictions on adults aged 80 
and older.
Previous research suggests that symptoms of mental 
illness can increase if treatment needs are not met.33,34 
Possible consequences of this unmet need include 
increased numbers of admissions to psychiatric units and 
presentations to emergency departments for mental 
illness, self-harm, and drug and alcohol misuse, and 
heightened suicide risk. Ongoing monitoring to assess 
whether rates continue to increase beyond expected levels 
is important for ensuring health services can meet 
future demand. Further research using linkages to NHS 
Hospital Episode Statistics will enable examination of 
self-harm separately among people presenting to primary 
care versus those presenting to hospital emergency 
departments. It is unclear how community-based services 
and voluntary organisations, which are an important 
source of support for people with mental illness, were 
affected. Some organisations reported increased demand, 
whereas others had little change in service use.35 
Additionally, the COVID-19 restrictions implemented in 
March, 2020, might have helped to reduce mental distress 
for some people, which might partly explain the 
reductions in contacts we observed. The potential for 
individuals to adapt to challenges and to experience post-
traumatic growth in response to major upheaval also 
warrants further research.36 However, as the crisis persists 
into the winter months and beyond, there are likely to be 
greater challenges with regard to the management of 
economic and social impacts. Encouraging individuals to 
seek support from health services when needed, 
despite COVID-19 restrictions, is an important public 
health message. Patients might have accessed support 
elsewhere, such as from non-statutory services; the 
potential longer-term reductions in primary care contact 
for mental illness and self-harm, as populations adapt to 
changing provision of mental health support, is an 
important topic for future research.
The main strength of our study is the broadly 
nationally representative setting, which included more 
than 14 million patients registered with general practices 
across the four nations of the UK. The use of two discrete 
data sources, the Aarum and GOLD databases, also 
enabled independent replication in our study. Although 
there have been a number of self-report surveys 
evaluating changes in mental health since the COVID-19 
crisis began, these are unlikely to capture effects on the 
most vulnerable groups such as those with existing 
mental illness.18 The surveys might also overestimate 
rates of mental illness and do not provide accurate 
information about clinical need.18
We acknowledge some limitations to our study. 
Recording of ethnicity within the CPRD was of 
insufficient quality to enable us to examine clinical 
contact among ethnic minority groups. Although we 
examined clinical contacts in all four nations of the UK, 
information on mental health referrals was not available 
in the CPRD data source for practices in England. Data 
from Northern Ireland, Scotland, and Wales are not fully 
representative of geographical coverage of patients and 
practice size; thus, findings might be less representative 
of smaller general practices.19 Patients from practices in 
the most deprived areas were over-represented in the 
study cohort, particularly in Northern Ireland and Wales. 
Although patterns observed for Northern Ireland, 
Scotland, and Wales were similar to those for England, 
the patient management software systems and the 
coding classification systems that contribute to the two 
CPRD databases used are different. Therefore, variation 
in the identification of mental illness and self-harm 
between the two databases in our study is possible. Some 
of the reduction in primary care-recorded mental illness 
and self-harm might have been a result of inaccuracies in 
coding due to the rapid changes and adaptations that 
GPs had to make, including a shift to remote consultation 
methods, during the early stages of the study period. 
Antidepressant and benzodiazepine medications have 
indications beyond treating mental illness, and therefore 
interpretation of findings associated with prescribing 
rates should take this into consideration. Although 
98% of the UK population is registered at an NHS GP 
surgery, certain patients are not represented in our study, 
including prisoners, private patients, those in some 
residential homes, and some people with no fixed 
address.19,20 Considering the relatively small incidence 
of self-harm compared with depression and anxiety 
disorders, and the potential delay in hospital-presenting 
self-harm episodes being added to patients’ primary care 
records, it is possible that not all primary care-recorded 
self-harm would have been captured in the last two 
months of our study period (August and September, 2020).
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The marked reduction in primary care-recorded mental 
illness and self-harm during the spring 2020 peak of the 
COVID-19 pandemic in the UK and the increased mental 
health burden resulting from the pandemic indicates 
untreated mental illness. Adults of working age, patients 
registered with practices located in deprived areas, and 
women and younger people who self-harm might have 
greater levels of undetected need. Addressing delays in 
diagnosis and treatment is a priority, particularly in these 
groups. Awareness of potential further reductions in help 
seeking and subsequent increases in the incidence of 
mental illness could help primary, secondary, and acute 
services prepare for changes in demand for mental 
health services.
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